1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > PharmaPoint: Acute Coronary Syndrome - Current and Future Players

PharmaPoint: Acute Coronary Syndrome - Current and Future Players

Summary

GlobalData has released its pharma report, “PharmaPoint: Acute Coronary Syndrome - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing ACS Market. The report identifies and analyses the key companies shaping and driving the global ACS market. The report provides insight into the competitive ACS landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.

Scope

- Investigation of current and future market competition for ACS
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of ACS sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving ACS market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What’s the next big thing in the global ACS market landscape? Identify, understand and capitalize

Table Of Contents

PharmaPoint: Acute Coronary Syndrome - Current and Future Players
1 Table of Contents

2 Introduction 12
2.1 Catalyst 12
2.2 Related Reports 13
2.3 Upcoming Related Reports 15
3 Market Outlook 16
3.1 Global Markets 16
3.1.1 Forecast 16
3.1.2 Drivers and Barriers - Global Issues 26
4 Current and Future Players 32
4.1 Overview 32
4.2 Trends in Corporate Strategy 38
4.3 Company Profiles 40
4.3.1 Amgen 40
4.3.2 AstraZeneca 42
4.3.3 Bristol-Myers Squibb 45
4.3.4 Daiichi Sankyo 48
4.3.5 Eli Lilly 50
4.3.6 GlaxoSmithKline 52
4.3.7 Janssen Pharmaceuticals (Johnson and Johnson) 55
4.3.8 The Medicines Company 56
4.3.9 Merck and Co. 60
4.3.10 Pfizer 63
4.3.11 Sanofi 66
5 Appendix 70
5.1 Bibliography 70
5.2 Abbreviations 72
5.3 Methodology 76
5.4 Forecasting Methodology 76
5.4.1 Methodology for Forecasting Selected Portions of the Diagnosed Prevalent ACS Population 76
5.4.2 Diagnosed Acute Coronary Syndrome Patients 77
5.4.3 Percent Drug-Treated Patients 78
5.4.4 General Pricing Assumptions 78
5.4.5 Generic Erosion 79
5.4.6 Pricing of Pipeline Agents 80
5.5 Physicians and Specialists Included in this Study 81
5.6 About the Authors 84
5.6.1 Author 84
5.6.2 Reviewer 84
5.6.3 Global Head of Healthcare 85
5.7 About GlobalData 86
5.8 Disclaimer 86

1.1 List of Tables

Table 1: Global Sales Forecasts ($bn) for ACS, 2013-2023 19
Table 2: Acute Coronary Syndrome Market - Drivers and Barriers, 2014 26
Table 3: Key Companies in the Acute Coronary Syndrome Market, 2014 37
Table 4: Amgen's Acute Coronary Syndrome Portfolio Assessment, 2014 42
Table 5: Amgen SWOT Analysis, 2014 42
Table 6: AstraZeneca's Acute Coronary Syndrome Portfolio Assessment, 2014 44
Table 7: AstraZeneca SWOT Analysis, 2014 45
Table 8: Bristol-Myers Squibb's Acute Coronary Syndrome Portfolio Assessment, 2014 47
Table 9: Bristol-Myers Squibb SWOT Analysis, 2014 47
Table 10: Daiichi Sankyo's Acute Coronary Syndrome Portfolio Assessment, 2014 49
Table 11: Daiichi Sankyo SWOT Analysis, 2014 50
Table 12: Eli Lilly's Acute Coronary Syndrome Portfolio Assessment, 2014 52
Table 13: Eli Lilly SWOT Analysis, 2014 52
Table 14: GlaxoSmithKline's Acute Coronary Syndrome Portfolio Assessment, 2014 54
Table 15: GlaxoSmithKline SWOT Analysis, 2014 54
Table 16: Janssen's Acute Coronary Syndrome Portfolio Assessment, 2014 56
Table 17: Janssen SWOT Analysis, 2014 56
Table 18: The Medicines Company's Acute Coronary Syndrome Portfolio Assessment, 2014 59
Table 19: The Medicines Company SWOT Analysis, 2014 60
Table 20: Merck's Acute Coronary Syndrome Portfolio Assessment, 2014 62
Table 21: Merck SWOT Analysis, 2014 63
Table 22: Pfizer's Acute Coronary Syndrome Portfolio Assessment, 2014 65
Table 23: Pfizer SWOT Analysis, 2014 66
Table 24: Sanofi's Acute Coronary Syndrome Portfolio Assessment, 2014 68
Table 25: Sanofi SWOT Analysis, 2014 69
Table 26: Price Sources and Calculations, by Country 79
Table 27: Physicians Surveyed, By Country 83

1.2 List of Figures

Figure 1: Global Sales for Acute Coronary Syndrome by Region, 2013-2023 21
Figure 2: Global* ACS Sales by Drug Class, 2013-2023 22
Figure 3: Global* Sales Forecast for PCSK9 mAbs, 2015-2023 23
Figure 4: Global* Sales Forecast of the New Antithrombotics, Xarelto and Zontivity, 2013-2023 24
Figure 5: Projected Global* Sales of ACS Drugs By Year, 2013-2023 25
Figure 6: Company Portfolio Gap Analysis in Acute Coronary Syndrome, 2013-2023 38

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Acute coronary syndrome (ACS)- Market Insights, Epidemiology and Market Forecast-2023

Acute coronary syndrome (ACS)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Acute coronary syndrome (ACS) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the ...

EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025

EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025

  • $ 3995
  • Industry report
  • August 2016
  • by Global Data

EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025 Summary Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences ...

Acute coronary syndrome (ACS) - Epidemiology Forecast To 2023

Acute coronary syndrome (ACS) - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight “Acute coronary syndrome (ACS) - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Acute coronary syndrome (ACS) in seven major markets (US, France, Germany, ...

Cardiac Markers

June 2016 $ 1995

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.